Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. - Wikidata - awgldk - TriplyDB

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

http://www.wikidata.org/entity/Q33754603

about

Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis How I treat pediatric acute myeloid leukemia Childhood acute myeloid leukaemia High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations.Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.Who is fit for allogeneic transplantation?Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.The adolescent and young adult with cancer: state of the art-- acute leukemias.Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.Molecular diagnosis of acute myeloid leukemia.Epigenetic regulation of miRNA genes in acute leukemia.Therapeutic targeting of c-KIT in cancer.Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia Novel therapies for children with acute myeloid leukaemia.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.How I treat paediatric relapsed acute myeloid leukaemia.Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia.Novel approaches to pediatric leukemia treatment.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

P2860

Q26771740-9E62ED96-71BA-4242-9E72-42BB33C57A5F Q26992280-E11894EC-D6E4-445C-890C-725A6F868104 Q27005960-FA1FB4E2-C9D3-4A55-837D-E328A7D42D8C Q33667247-8858B53B-D93E-41E3-890C-B72A45A91A16 Q33758306-015DFA7A-5E52-4ED5-898F-8B62B50052A2 Q34052581-60B75D48-504B-4074-8C6F-FEE3BEDBF60E Q34106837-12E8B2B4-4879-4146-9999-AA5A1E28E887 Q34663691-CE89AECD-CBF7-4A79-9651-7B67AAB17ABB Q34764504-F36C090C-CD5F-4B00-911E-0CDCE976F8A9 Q35025091-904B0F1A-C845-48B1-A4A7-BDC295ACAD4F Q35046171-2BC211B4-881A-4BE9-9092-E165DC08A1DF Q35265916-4920FAFB-7B23-48FA-9046-222DB40965DE Q35525313-E22DEFC5-3164-4E76-BE9B-9B4B811C8B89 Q35606252-95802BD6-9810-45B5-9EC2-698127E373D6 Q35651744-AF8F2850-AB93-4172-AB79-43434D51AF7F Q35660739-E3A80C0A-4970-40E0-9EB3-3DF5F2CF9C84 Q36053792-04A34DF0-CC75-4C6A-897E-78768DF20B88 Q36303319-80B9B760-7393-4F68-8180-BA7DCB3732A3 Q36548080-41F5A04A-0012-4472-806A-4F18154C4FB4 Q36917869-DC280F07-E7AB-4185-A2B3-707D7C3200C0 Q36919799-4ABA82EB-67DE-46C4-BA0C-07763663F9B0 Q37134753-B62DC90E-B31A-46DD-966F-F5A46A3EF8C2 Q37295112-33C58D4D-A1E6-467D-AFB9-4E636D2394D3 Q37372832-70AB206A-929A-4666-944D-4F6EE28A357F Q37643136-497A3D46-E655-4810-8057-B938D6E809B4 Q37659087-150564BF-8A4F-4B07-8D5E-4AF3C89FB84D Q37809866-EBC67700-B30C-43B0-A673-EB3023AD7CE4 Q37965026-C908984C-C61F-465B-9BDF-8DA065BD52AB Q38057806-0AC2D96E-7F9F-428C-9400-469AD451AC88 Q38068816-11ADE37A-554C-4CC2-BCD4-0A154E67D536 Q38096798-C64C64D0-5CB2-449B-ABDB-14F552ADE7C1 Q38196743-7C0A2266-306A-4163-BA40-A52E7CC73955 Q38212509-F41A9A5A-8905-4B19-9B42-58F294A488E3 Q38263126-48E6521D-6FD2-41A5-938F-F1354F27C8B6 Q38315894-DDD786A6-E4E0-4AB6-A858-013406C15945 Q38500371-CF354A7A-BBE9-40A1-A744-6549CB6FC136 Q38904250-5FE5FC8D-9088-4754-AE84-EF9F3AA573A9 Q40100589-9882DED2-9FF0-4E21-BC27-9533D462899C Q41823976-D8EBC29E-E79D-421D-9044-B9F58031DE76 Q41973082-D8B425F1-1FAA-4886-943D-771AD85E82E1

P2860

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

http://www.wikidata.org/entity/Q33754603

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prevalence and prognostic sign ...... rative trials for de novo AML.

@ast

Prevalence and prognostic sign ...... rative trials for de novo AML.

@en

type

label

Prevalence and prognostic sign ...... rative trials for de novo AML.

@ast

Prevalence and prognostic sign ...... rative trials for de novo AML.

@en

prefLabel

Prevalence and prognostic sign ...... rative trials for de novo AML.

@ast

Prevalence and prognostic sign ...... rative trials for de novo AML.

@en

P1433

Q33754603-F8D9F0DD-2883-4E07-8E46-670C0BFFD55A

P1476

Q33754603-C250B5BA-4996-4D20-B2AE-6665977F1A42

P2093

Q33754603-026A774E-3D95-416E-BBC8-FCD08A3E7712

Q33754603-239CB8B0-42A3-45DF-8F4E-F61A3AD5B194

Q33754603-2942CF99-0B81-48F3-B0F2-11645C251E83

Q33754603-2956CB2D-7AA3-4CDB-8D7C-EE1A8F2154A8

Q33754603-2EB7CE5C-7DCF-4C7D-A0A9-82242CF32F9E

Q33754603-3F3261D1-CD41-4969-89C3-5B626B317FAB

Q33754603-4B42E222-1B83-408B-853F-291F61295A3F

Q33754603-5F1DD3C4-B2F6-4ECD-A772-4745533BC6EE

Q33754603-6024F2ED-A7C2-4F87-8566-3DCEA14A13D9

Q33754603-70E18437-375D-4953-A890-821CDD71FA0B

P2860

Q33754603-099BF0B3-74D4-4DE7-BB03-D0784615DA79

Q33754603-0C358E16-AFA1-4BD7-8A43-80EA0B5252F2

Q33754603-1CE16EA7-94BE-43AD-B289-40C139524074

Q33754603-416C6289-6898-401C-A090-13ED1D800DD2

Q33754603-458074BC-E741-4861-AA81-EA0DB8B944F1

Q33754603-4644CB39-B447-4DFB-9E0F-218864581FD0

Q33754603-46A427B8-4641-42F1-8C80-F611B009D02B

Q33754603-4C1F3B35-8349-4E8A-BC52-501A54D51A19

Q33754603-5BE2A411-73A0-4C21-9A9C-F6BF7C1D0FF9

Q33754603-5DE59FB6-970D-4572-B2FC-745596465A49

P304

Q33754603-2C6ECA31-7812-45BF-AB21-0D60C183F6E5

P31

Q33754603-8CFB5EAA-34CA-41A3-B08C-709A32698E75

P356

Q33754603-F38F5847-394B-40FB-A6F8-355A90A63788

P407

Q33754603-82318C40-AD4B-425C-8541-42E01A8560DD

P433

Q33754603-795AA1A6-28B8-43C8-A7D2-AC132D249B30

P478

Q33754603-934DBB5B-43BF-4478-9C11-49AFFBEEBC23

P50

Q33754603-47FFE084-D334-4256-9883-F1AD1432E5D9

Q33754603-780BA1D0-96AF-429C-AE4F-7C2155DB02C8

Q33754603-91F9BDDA-8713-464B-8057-38A076B3D1CD

P577

Q33754603-5527B8B2-5840-4481-A884-62B054B59D08

P5875

Q33754603-8602D5B3-F7CE-4E4C-B083-F53BDD48182B

P698

Q33754603-27FB9F8D-DEB6-47A4-A1C9-12DFE5720C43

P932

Q33754603-ACDC9481-C0C9-47C7-AFFC-015E4F954E20

P356

BLOOD-2009-09-241075

P1433

P1476

Prevalence and prognostic sign ...... erative trials for de novo AML

@en

P2093

Betsy Hirsch

http://www.w3.org/2001/XMLSchema#string

Beverly J Lange

http://www.w3.org/2001/XMLSchema#string

Craig Hurwitz

http://www.w3.org/2001/XMLSchema#string

David Becton

http://www.w3.org/2001/XMLSchema#string

Gary Dahl

http://www.w3.org/2001/XMLSchema#string

Howard J Weinstein

http://www.w3.org/2001/XMLSchema#string

Irwin D Bernstein

http://www.w3.org/2001/XMLSchema#string

Jerald P Radich

http://www.w3.org/2001/XMLSchema#string

Jessica A Pollard

http://www.w3.org/2001/XMLSchema#string

Myron Chang

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant

Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

Clinical implications of FLT3 mutations in pediatric AML.

FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.

P304

2372-2379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-09-241075

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Michael C. Heinrich

P577

2010-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40894767

http://www.w3.org/2001/XMLSchema#string

P698

20056794

http://www.w3.org/2001/XMLSchema#string

P932

2845895

http://www.w3.org/2001/XMLSchema#string